MetaCap

Redhill Biopharma Ltd. ADR (RDHL)

NASDAQ: RDHLHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.281-0.0423 (-13.08%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RDHL stock chart

Technical analysis

Key statistics

All statistics
52-week range
0.281 – 1.60
Day range
0.281 – 0.3385
Volume / Avg
24.25K / 2.08M
Beta
—

52-week range

$0.281$1.60

RDHL stock today

Shares of Redhill Biopharma (RDHL) finished lower on Nov 20 at $0.281, a drop of 13.08% or $0.0423 per share, versus the S&P 500's 3.70% decline. Trading was light, with 24.25K shares changing hands, about 1% of the average daily volume. At this level, RDHL sits near the bottom of its 52-week range of $0.281 to $1.60: 82.4% below the high and 0.0% above the low.

Redhill Biopharma has posted a net loss over the last twelve months (EPS of $0.00), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Redhill Biopharma

Company profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Dror Ben-Asher
Headquarters
Tel Aviv-Yafo
Employees
13

Financial highlights

Full financials

In fiscal 2024, Redhill Biopharma generated $8.0 million in revenue, up 23.2% from fiscal 2023. Redhill Biopharma reported a net loss of $8.3 million, compared with net income of $23.9 million a year earlier. Gross margin was 60.3% (up from 47.0%) and operating margin -181.7%.

Redhill Biopharma annual revenue, net income and EPS
Fiscal yearFY 2024FY 2023FY 2022FY 2021FY 2020
Revenue$8.04M$6.53M$61.80M$85.76M$64.36M
Growth+23.17%-89.43%-27.94%+33.25%+923.03%
Net income$-8.27M$23.92M$-71.67M$-97.74M$-76.17M
EPS (diluted)$0.00$0.01$-0.12$-0.21$-0.21

RDHL news

All RDHL news

Redhill Biopharma peers

Health Care sector
RDHL peer companies
CompanyPrice% ChgMarket capCompare
DRMADermata Therapeutics Inc.0.5095-4.23%$2.51Mvs RDHL
GRIGRI Bio Inc.1.120.00%$2.45Mvs RDHL
ONCOOnconetix Inc.2.89-8.54%$2.37Mvs RDHL
HCWBHCW Biologics Inc.0.7491+1.90%$2.35Mvs RDHL
MBIOMustang Bio Inc.0.3541-4.30%$2.69Mvs RDHL
TRAWTraws Pharma Inc.0.175-23.91%$2.69Mvs RDHL
ERNAErnexa Therapeutics Inc.1.36-16.56%$2.30Mvs RDHL
LABTLakewood-Amedex Biotherapeutics Inc.0.2449+15.03%$2.19Mvs RDHL

Indexes, lists and sector

Redhill Biopharma stock FAQ

What is Redhill Biopharma's stock price today?

RDHL last traded at $0.281 as of Nov 20, 4:00 PM EST, down 13.08% on the day. Prices are delayed at least 15 minutes.

Who is Redhill Biopharma's CEO?

Mr. Dror Ben-Asher is the chief executive officer of Redhill Biopharma Ltd. ADR, which has about 13 employees.

What is the RDHL 52-week high?

The 52-week high for RDHL is $1.60 and the 52-week low is $0.281. The stock is currently 82.4% below its high.

Compare RDHL